The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Chugai Lifts Shipment Curbs for Edirol, Easing Active Vitamin D3 Shortages
Chugai Pharmaceutical lifted its shipment restrictions for its osteoporosis treatment Edirol (eldecalcitol) on September 10, a step forward to ease ongoing supply shortages surrounding active vitamin D3 products. With disruptions continuing for other drugs in the class, however, it will…
To read the full story
Related Article
- Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
July 21, 2021
- Kyowa Suspending Alfacalcidol Supply; Chugai Curbs Further Products
July 21, 2021
- Kyosomirai Controls Shipments for Generic Calcitriol Amid Vitamin D3 Preparation Shortage
July 20, 2021
- Teijin Restricting Shipments for Onealfa after Curbs on Edirol
July 13, 2021
- Edirol, Generic Drugs All Now Face Supply Curbs as Nichi-Iko Woes Spill Over
July 8, 2021
- Nichi-Iko Halts Supplies of Some Edirol Generic Products, Re-Supply Expected for September
June 22, 2021
BUSINESS
- Sanofi Files Dupixent for CSU in Children Aged 2-11 in Japan
December 26, 2025
- Enhertu Wins 5th China Indication in HER2-Low/Ultralow Breast Cancer
December 26, 2025
- SymBio Bags Rights to Develop Antiviral Brincidofovir for Alzheimer’s
December 26, 2025
- Dayvigo Wins Triple Crown in November HP Promotion List: Intage
December 26, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…